GLP1R and obesity disorder: The 2023 American Academy of Pediatrics (AAP) Clinical Practice Guideline formally recommends considering pharmacotherapy, including GLP-1 RAs, for adolescents ≥12 years with obesity as part of a comprehensive care plan, positioning these agents between lifestyle therapy and bariatric surgery in the treatment algorithm [13].